Evidence map›Paper›PMID 34400692›Full record

ArticleScientific reports2021

Prognostic role of neoplastic markers in Takotsubo syndrome.

Francesco Santoro, Tecla Zimotti, Adriana Mallardi, Alessandra Leopizzi, Enrica Vitale, Nicola Tarantino, Armando Ferraretti, Antonio Giovanni Solimando, Vito Racanelli, Massimo Iacoviello and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Takotsubo Syndrome: Translational Implications and Pathomechanisms.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco SantoroDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Tecla ZimottiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Adriana MallardiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Alessandra LeopizziDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Enrica VitaleDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Nicola TarantinoDepartment of Medicine, Montefiore Medical Center, Cardiology Division, Bronx, NY, USA.
Armando FerrarettiDepartment of Cardiology, Caduti Di Guerra Hospital, Canosa, Italy.
Antonio Giovanni SolimandoDepartment of Biomedical Sciences and Human Oncology, Unit of Internal Medicine "Baccelli", University of Bari, Bari, Italy.
Vito RacanelliDepartment of Biomedical Sciences and Human Oncology, Unit of Internal Medicine "Baccelli", University of Bari, Bari, Italy.
Massimo IacovielloDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Michele CannoneDepartment of Cardiology, Bonomo Hospital, Andria, Italy.
Matteo Di BiaseDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. nd.brunetti@unifg.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Takotsubo syndrome (TTS) is an acute heart failure syndrome with significant rates of in and out-of-hospital mayor cardiac adverse events (MACE). To evaluate the possible role of neoplastic biomarkers [CA-15.3, CA-19.9 and Carcinoembryonic Antigen (CEA)] as prognostic marker at short- and long-term follow-up in subjects with TTS. Ninety consecutive subjects with TTS were enrolled and followed for a median of 3 years. Circulating levels of CA-15.3, CA-19.9 and CEA were evaluated at admission, after 72 h and at discharge. Incidence of MACE during hospitalization and follow-up were recorded. Forty-three (46%) patients experienced MACE during hospitalization. These patients had increased admission levels of CEA (4.3 ± 6.2 vs. 2.2 ± 1.5 ng/mL, p = 0.03). CEA levels were higher in subjects with in-hospital MACE. At long term follow-up, CEA and CA-19.9 levels were associated with increased risk of death (log rank p < 0.01, HR = 5.3, 95% CI 1.9-14.8, HR = 7.8 95% CI 2.4-25.1, respectively, p < 0.01). At multivariable analysis levels higher than median of CEA, CA-19.9 or both were independent predictors of death at long term (Log-Rank p < 0.01). Having both CEA and CA-19.9 levels above median (> 2 ng/mL, > 8 UI/mL respectively) was associated with an increased risk of mortality of 11.8 (95% CI 2.6-52.5, p = 0.001) at follow up. Increased CEA and CA-19.9 serum levels are associated with higher risk of death at long-term follow up in patients with TTS. CEA serum levels are correlated with in-hospital MACE.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenCardiovascular DiseasesComorbidityC-Reactive ProteinFemaleFollow-Up StudiesHeart VentriclesHospitalizationHospital MortalityHumansInterleukinsMaleBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenC-Reactive ProteinInterleukinsMucin-1Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin I

Identifiers

PMID34400692
PMCPMC8368165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.